This Small Biotech Stock Is Surging Today. Here's Why.
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis (NVS) is buying the small biotech firm for $1.4 billion to complement its cardiovascular pipeline is giving Tourmaline a fresh boost.
Novartis: Pipeline Progress And Buyback Drive Upside
Novartis delivered strong Q2 results with 24% net income growth and robust sales from key drugs like Kisqali and Pluvicto, supporting our positive outlook. Despite generic competition and tariff concerns, Novartis' pipeline and US investment underpin our confidence. A $10 billion share buyback, higher guidance, and disciplined capital allocation further strengthen the Novartis investment case. We maintain our Buy rating.
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Here's Why Novartis (NVS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?
Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.
Exploring Analyst Estimates for Novartis (NVS) Q2 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Novartis (NVS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
